{"DataElement":{"publicId":"6299952","version":"1","preferredName":"Myelodysplastic Syndrome Disease Response Evaluation Status","preferredDefinition":"Text term to describe the myelodysplastic syndrome disease response status based on hematologic evaluation.","longName":"MDS_DZ_RESP_STS","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"6299940","version":"1","preferredName":"Myelodysplastic Syndrome Disease Response Evaluation","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)_The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"2459218v1.0:6118200v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2459218","version":"1","preferredName":"MDS","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","longName":"C3247","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F0AEBD7-94FD-60D5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-15","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-03-15","modifiedBy":"ONEDATA","dateModified":"2006-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6118200","version":"1","preferredName":"Disease Response Evaluation","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C50995:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66EE8121-3F37-01B4-E053-F662850AB193","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-08","modifiedBy":"ONEDATA","dateModified":"2018-03-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CDF8C78-AD8E-5EAA-E053-F662850A4FBC","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"SOKKERL","dateModified":"2018-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6297969","version":"1","preferredName":"Myelodysplastic Syndrome Response Status","preferredDefinition":"A condition or state at a particular time.","longName":"MDS_RESP_STS","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Partial Remission","valueDescription":"Partial Remission","ValueMeaning":{"publicId":"3951935","version":"1","preferredName":"Partial Remission","longName":"3951935","preferredDefinition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Remission","conceptCode":"C18058","definition":"A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EB155E17-C5B7-CEC3-E040-BB89AD4342C2","latestVersionIndicator":"Yes","beginDate":"2013-11-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CE15222-0391-2B24-E053-F662850A6CE2","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Complete Remission","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"3854972","version":"1","preferredName":"Complete Remission","longName":"3854972","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3DF4512-86FD-A83E-E040-BB89AD431C6D","latestVersionIndicator":"Yes","beginDate":"2013-08-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CE15222-039C-2B24-E053-F662850A6CE2","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"Relapse","ValueMeaning":{"publicId":"5035791","version":"1","preferredName":"Relapse","longName":"5035791","preferredDefinition":"The return of signs and symptoms of cancer after a period of improvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse","conceptCode":"C0699753","definition":"The return of signs and symptoms of cancer after a period of improvement.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223EE1E8-286D-61CF-E050-BB89AD436EF1","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CE1C39D-100E-50C8-E053-F662850A9F96","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Stable Disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2982985","version":"1","preferredName":"Stable Disease","longName":"2982985","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C991ADD-0176-711A-E040-BB89AD432C85","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CE1C39D-1019-50C8-E053-F662850A9F96","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Hematologic improvement   erythroid (HI-E)","valueDescription":"Hematologic Improvement-Erythroid Response","ValueMeaning":{"publicId":"6301228","version":"1","preferredName":"Hematologic Improvement-Erythroid Response","longName":"6301228","preferredDefinition":"An improvement in erythrocyte count as a response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Erythroid Response","conceptCode":"C123585","definition":"An improvement in erythrocyte count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-747B-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CEA4F9D-7498-32DD-E053-F662850AE25B","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Hematologic improvement   neutrophil (HI-N)","valueDescription":"Hematologic Improvement-Neutrophil Response","ValueMeaning":{"publicId":"6301230","version":"1","preferredName":"Hematologic Improvement-Neutrophil Response","longName":"6301230","preferredDefinition":"An improvement of neutrophil count as a response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Neutrophil Response","conceptCode":"C123586","definition":"An improvement of neutrophil count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-74A5-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CEA4F9D-74C2-32DD-E053-F662850AE25B","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Hematologic improvement   platelet (HI-P)","valueDescription":"Hematologic Improvement-Platelet Response","ValueMeaning":{"publicId":"6301232","version":"1","preferredName":"Hematologic Improvement-Platelet Response","longName":"6301232","preferredDefinition":"An improvement of platelet count as a response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematologic Improvement-Platelet Response","conceptCode":"C123587","definition":"An improvement of platelet count as a response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-74CF-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CEA4F9D-74EC-32DD-E053-F662850AE25B","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"},{"value":"Marrow CR","valueDescription":"Marrow Complete Response","ValueMeaning":{"publicId":"6301234","version":"1","preferredName":"Marrow Complete Response","longName":"6301234","preferredDefinition":"A decrease in the number of bone marrow plasma cells to protocol-defined level(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marrow Complete Response","conceptCode":"C123591","definition":"A decrease in the number of bone marrow plasma cells to protocol-defined level(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CEA4F9D-74F9-32DD-E053-F662850AE25B","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CEA4F9D-7516-32DD-E053-F662850AE25B","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"ONEDATA","dateModified":"2018-05-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CBA2B24-22D6-71EC-E053-F662850AD6F3","latestVersionIndicator":"Yes","beginDate":"2018-05-21","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-21","modifiedBy":"SOKKERL","dateModified":"2018-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Myelodysplastic Syndrome resp","type":"Preferred Question Text","description":"Myelodysplastic Syndrome response","url":null,"context":"NCIP"}],"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CDF1573-C110-5EAE-E053-F662850A26BB","latestVersionIndicator":"Yes","beginDate":"2018-05-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-05-23","modifiedBy":"SOKKERL","dateModified":"2018-05-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}